Document is current
Any future updates will be listed below
-
Authors
Cristescu, Razvan https://orcid.org/0000-0002-9978-0339
Aurora-Garg, Deepti
Albright, Andrew
Xu, Lei
Liu, Xiao Qiao
Loboda, Andrey
Lang, Lixin
Jin, Fan
Rubin, Eric H
Snyder, Alexandra https://orcid.org/0000-0002-2606-3523
Lunceford, Jared
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01295827 at ClinicalTrials.govnct01704287 at ClinicalTrials.govDocuments that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
https://doi.org/10.1016/s0140-6736(14)60958-2
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct01905657 at ClinicalTrials.govDocuments that mention this clinical trial
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
https://doi.org/10.1016/j.ejca.2016.07.018
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
https://doi.org/10.1016/j.ejca.2013.06.027
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
https://doi.org/10.1016/s0140-6736(14)60958-2
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
nct01848834 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
https://doi.org/10.1016/j.lungcan.2015.02.007
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02054806 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2021-003026
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
https://doi.org/10.1136/gutjnl-2015-310839
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct02256436 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
https://doi.org/10.1136/ijgc-2019-001012
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Phase 2 study of pembrolizumab in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2019-000347
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
https://doi.org/10.1136/thoraxjnl-2017-211416
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct02255097 at ClinicalTrials.govDocuments that mention this clinical trial
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer
https://doi.org/10.1136/bmjopen-2018-028287
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.4512
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
nct02335411 at ClinicalTrials.govDocuments that mention this clinical trial
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2021-003026
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
https://doi.org/10.1136/esmoopen-2017-000257
nct02370498 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia
https://doi.org/10.1136/bmjopen-2023-076898
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
https://doi.org/10.1200/po-24-00456
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02447003 at ClinicalTrials.govDocuments that mention this clinical trial
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
https://doi.org/10.1200/po-24-00456
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
https://doi.org/10.1007/s10120-021-01227-z
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
https://doi.org/10.1136/jitc-2023-006920
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
https://doi.org/10.1007/s10120-021-01200-w
nct02674061 at ClinicalTrials.govDocuments that mention this clinical trial
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
https://doi.org/10.1200/po.22.00317
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
https://doi.org/10.1136/jclinpath-2016-203874
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02787005 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
https://doi.org/10.1136/jitc-2020-sitc2020.0346
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme (N/A)
- License Information
